Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2019-08-07 Director's Dealing
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
108年07月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by company insiders, including directors, supervisors, and managers, showing their current and initial holdings, pledged shares, and related information. It is a disclosure of insider shareholdings and changes, typical of insider trading or director dealings reports. There is no indication of financial statements, earnings data, or meeting materials. The document length is short (2914 characters) and focuses solely on insider shareholdings. Therefore, it fits the category of Director's Dealing (DIRS).
2019-08-07 Chinese
公告本公司含麻藥凝膠新劑型玻尿酸愛霓密絲瀲灩及含麻藥 凝膠新劑型雅緻輕感皮下填補劑二項產品獲得中華民國衛生福利 部(TFDA)核發第三類醫材銷售許可證。
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company (科妍生物科技股份有限公司) reporting that two new medical products have received sales permits from the Taiwan Food and Drug Administration (TFDA). It includes details about the products and the permit numbers. The document is brief (1030 characters) and does not contain financial data, financial statements, or detailed management discussion. It is an announcement of a regulatory approval event rather than a financial report or management update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a voting result, board change, or capital update. Given the nature and length, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-08-06 Chinese
108年7月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a company named 科妍, providing information about fund loans and endorsement guarantees for the current and previous months, with amounts all zero. The content is very short (601 characters) and consists mainly of tabular data about financial guarantees and loans, without any detailed financial statements, management discussion, or regulatory certifications. It does not contain any narrative or detailed financial analysis typical of annual or interim reports. It also does not announce any voting results, management changes, or legal proceedings. Given the brevity and nature of the data, this document fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-08-06 Chinese
108年7月營業收入
Regulatory Filings Classification · 95% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 科妍, with data for July 2019 (民國108年07月). It includes percentage changes compared to the previous year and explanatory notes about accounting standards and reporting practices. The document is very short (766 characters) and does not contain detailed financial statements or comprehensive analysis. It appears to be a regulatory or compliance disclosure of revenue figures rather than a full financial report or earnings release. There is no indication of a conference call transcript, management discussion, or audit report. It is not an announcement of a meeting or voting results. Given the nature and length, this fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2019-08-06 Chinese
公告本公司HYAJOINT Plus一針劑型及HYA-JOINT三針劑型 關節腔注射劑取得印尼國家產品銷售許可證。
Regulatory Filings Classification · 95% confidence The document is a short announcement (868 characters) from a listed company (科妍) reporting that its products have obtained a national sales permit in Indonesia. It includes details about the permit and the company's plans for marketing and sales through a partner. There is no financial data, no report attached or referenced, and no indication of a meeting or voting results. The content is a regulatory announcement about a business development event. It does not fit into categories like Annual Report, Earnings Release, or Management Report. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-07-26 Chinese
公告本公司國內第一次無擔保轉換公司債轉換價格調整事宜
Capital/Financing Update Classification · 95% confidence The document is a short announcement (643 characters) from a company about an adjustment in the conversion price of its domestic unsecured convertible bonds due to dividend distribution. It specifies the new conversion price and the effective date. There is no detailed financial report or comprehensive data, only a specific capital/financing update related to convertible bonds. This fits the Capital/Financing Update (CAP) category rather than a full financial report or regulatory filing. The document is not a report publication announcement or certification, but a direct update on capital structure changes.
2019-07-26 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.